Biotech Company Asceneuron Raises $100M for New Alzheimer’s Drug 

Asceneuron, a Swiss biotech company, has successfully raised $100 million to develop drug therapies targeting proteins associated with Alzheimer’s disease and other brain conditions. The funding will advance the clinical development of OGA inhibitors, with the lead asset ASN51 progressing to Phase 2 for Alzheimer’s treatment. CEO Barbara A. Pavik is excited about the potential of ASN51 to expand treatment options. The drug aims to prevent protein aggregation in the brain, a key factor in Alzheimer’s and Parkinson’s diseases. Asceneuron also sees potential in treating Parkinson’s disease and amyotrophic lateral sclerosis. This funding comes at a transformative time for Alzheimer’s treatment, with recent breakthroughs in biomarker testing and the approval of disease-modifying therapies like donanemab. Novo Holdings Senior Partner Naveed Siddiqi believes Asceneuron’s oral small molecule approach could change the way neurodegenerative diseases are treated.